Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.46 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.30 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126232 | 0.81 | NOS3 (0.45) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL10272610 | 0.79 | NOS3 (0.36) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL18062083 | 0.79 | ESR1 (0.38) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL20288204 | 0.79 | NOS3 (0.35) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL6486053 | 0.79 | HCRTR1 (0.37) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL10272611 | 0.79 | NOS3 (0.35) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL10271475 | 0.79 | NOS3 (0.35) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL16414636 | 0.78 | NOS3 (0.50) | NOS3NOS2NOS1ALDH1A1UHRF1 | |
| SCHEMBL15417759 | 0.78 | NOS3 (0.44) | NOS3NOS2NOS1ALDH1A1CCR1 | |
| SCHEMBL15417381 | 0.78 | NOS3 (0.38) | NOS3NOS2NOS1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20220144855-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144856-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, A PLURALITY OF HOST MATERIALS, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220045281-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2022-02-10 | — | — | US | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-9505748-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-22 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NOS3 2801/4885NOS2 3530/4885NOS1 2447/4885 |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NOS3 2801/4885NOS2 3530/4885NOS1 2447/4885 |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | NOS3 866/4885NOS2 897/4885NOS1 1614/4885 |
| US-20220045281-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ELAVL1, ICOSLG, OR10J3 | NOS3 1775/4885NOS2 1131/4885NOS1 1382/4885 |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | NOS3 866/4885NOS2 897/4885NOS1 1614/4885 |
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | NOS3 2270/4885NOS2 2140/4885NOS1 862/4885 |
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | MYH10, MYLK, MKI67 | NOS3 416/4885NOS2 1820/4885NOS1 1076/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | NOS3 4604/4885NOS2 4564/4885NOS1 4522/4885 |
| US-20220144855-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | OR10J3, ICOSLG, EPCAM | NOS3 2071/4885NOS2 1661/4885NOS1 1908/4885 |
| US-20220144856-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, A PLURALITY OF HOST MATERIALS, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | OR10J3, L1CAM, EPCAM | NOS3 2850/4885NOS2 2301/4885NOS1 2280/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | NOS3 4605/4885NOS2 4466/4885NOS1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.